Viking Therapeutics Reports Q3 2026: Oral Phase 3 Initiated, Positive Maintenance Data, Cash Jumps to $960M

What happened

Viking Therapeutics announced Q3 2026 results, confirming initiation of the SUNRISE Phase 3 program for oral VK2735, a milestone previously flagged as critical in the prior analysis. Top-line results from the VK2735 maintenance dosing study were positive, with Part 2 of the study initiated, addressing a key uncertainty around durability of weight loss. The company also reported a strong quarter-end cash position of $960 million, significantly up from $603 million at Q1 2026, alleviating near-term financing concerns and likely reflecting recent capital raises. Pipeline progress continues with VANQUISH Phase 3 trials advancing and the Phase 1 SAD of amylin agonist VK3019 nearing completion, though the press release lacked detailed efficacy and tolerability data from the maintenance study. These developments reduce execution and financing risks identified in the previous WAIT rating, but the competitive landscape and the need for differentiation in the oral obesity market remain prominent.

Implication

The $960 million cash position and confirmation of the oral Phase 3 start address the two biggest risks flagged in earlier analysis: shelf expiry and potential timeline slippage into 2027. However, the increase in cash likely came from substantial equity issuance, so shareholders should evaluate dilution against the benefit of derisking. Positive top-line maintenance data is encouraging, but the lack of specific efficacy numbers or tolerability metrics means the market may await the full dataset before fully re-rating the stock. The initiation of SUNRISE Phase 3 trials is a necessary step, but the oral space is now crowded with approved competitors, so Viking's differentiation will hinge on detailed Phase 2 data and Phase 3 design choices. Overall, the risk-reward has improved, but a full upgrade to BUY would require confirmation that the maintenance data demonstrates clinically meaningful durability and that the oral program has a viable path to market.

Thesis delta

The thesis shifts from a WAIT stance focused on pending maintenance data and financing uncertainty to a more constructive outlook as both catalysts have been addressed. Positive top-line maintenance results and the initiation of oral Phase 3 reduce key risks, but the lack of detailed data and potential dilution warrant maintaining a cautious HOLD rating rather than an outright BUY. The next major inflection will be full maintenance data presentation and initial oral Phase 3 enrollment progress.